{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T12:28:11Z","timestamp":1785587291248,"version":"3.56.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T00:00:00Z","timestamp":1686960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T00:00:00Z","timestamp":1686960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-023-03221-6","type":"journal-article","created":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T08:02:08Z","timestamp":1686988928000},"page":"3519-3526","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy of second and third lines of treatment in advanced soft tissue sarcomas: a real-world study"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7356-5043","authenticated-orcid":false,"given":"Laura","family":"Gutierrez-Sainz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Martinez-Fdez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Pedregosa-Barbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Alameda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Vi\u00f1al","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Villamayor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Martinez-Recio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Perez-Wert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Pertejo-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Gallego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Martinez-Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Zamora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Mendiola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Feliu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7257-5642","authenticated-orcid":false,"given":"Andres","family":"Redondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,17]]},"reference":[{"key":"3221_CR1","unstructured":"Fletcher C (2020) WHO Classification of tumours: Soft Tissue and Bone Tumours (WHO Classification of Tumours, 5th ed; International Agency for Research on Cancer. Vol 3, Lyon, France"},{"key":"3221_CR2","doi-asserted-by":"publisher","unstructured":"Stiller CA, Trama A, Serraino D, Rossi S, Navarro C, Chirlaque MD, et al; RARECARE Working Group (2013) Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. Eur J Cancer. 49(3): 684\u201395. https:\/\/doi.org\/10.1016\/j.ejca.2012.09.011","DOI":"10.1016\/j.ejca.2012.09.011"},{"issue":"7","key":"3221_CR3","doi-asserted-by":"publisher","first-page":"815","DOI":"10.6004\/jnccn.2022.0035","volume":"20","author":"M von Mehren","year":"2022","unstructured":"von Mehren M, Kane JM, Agulnik M, Bui MM, Carr-Ascher J, Choy E, et al. Soft tissue sarcoma, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(7):815\u201333. https:\/\/doi.org\/10.6004\/jnccn.2022.0035.","journal-title":"J Natl Compr Canc Netw."},{"issue":"3","key":"3221_CR4","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3322\/caac.21605","volume":"70","author":"AC Gamboa","year":"2020","unstructured":"Gamboa AC, Gronchi A, Cardona K. Soft-tissue sarcoma in adults: an update on the current state of histiotype-specific management in an era of personalized medicine. CA Cancer J Clin. 2020;70(3):200\u201329. https:\/\/doi.org\/10.3322\/caac.21605.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"3221_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1080\/13577140020008066","volume":"4","author":"VH Bramwell","year":"2000","unstructured":"Bramwell VH, Anderson D, Charette ML. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma: a meta-analysis and clinical practice guideline. Sarcoma. 2000;4(3):103\u201312. https:\/\/doi.org\/10.1080\/13577140020008066.","journal-title":"Sarcoma"},{"issue":"1","key":"3221_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s11864-019-0606-9","volume":"20","author":"M Meyer","year":"2019","unstructured":"Meyer M, Seetharam M. First-line therapy for metastatic soft tissue sarcoma. Curr Treat Options Oncol. 2019;20(1):6. https:\/\/doi.org\/10.1007\/s11864-019-0606-9.","journal-title":"Curr Treat Options Oncol"},{"key":"3221_CR7","doi-asserted-by":"publisher","unstructured":"Judson I, Verweij J, Gelderblom H, Hartmann JT, Sch\u00f6ffski P, Blay JY, et al; European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (2014) Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 15(4): 415-23. https:\/\/doi.org\/10.1016\/S1470-2045(14)70063-4","DOI":"10.1016\/S1470-2045(14)70063-4"},{"key":"3221_CR8","doi-asserted-by":"publisher","unstructured":"Gronchi A, Miah AB, Dei Tos AP, Abecassis N, Bajpai J, Bauer S, et al (2021) ESMO Guidelines Committee, EURACAN and GENTURIS. Electronic address: clinicalguidelines@esmo.org. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 32(11): 1348\u20131365. https:\/\/doi.org\/10.1016\/j.annonc.2021.07.006","DOI":"10.1016\/j.annonc.2021.07.006"},{"issue":"5","key":"3221_CR9","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1007\/s12094-020-02534-0","volume":"23","author":"FA de Juan","year":"2021","unstructured":"de Juan FA, \u00c1lvarez \u00c1lvarez R, Casado Herr\u00e1ez A, Cruz Jurado J, Estival Gonz\u00e1lez A, Mart\u00edn-Broto J, et al. SEOM clinical guideline of management of soft-tissue sarcoma (2020). Clin Transl Oncol. 2021;23(5):922\u201330. https:\/\/doi.org\/10.1007\/s12094-020-02534-0.","journal-title":"Clin Transl Oncol"},{"issue":"13","key":"3221_CR10","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1186\/1471-2407-13-385","volume":"13","author":"S Sharma","year":"2013","unstructured":"Sharma S, Takyar S, Manson SC, Powell S, Penel N. Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review. BMC Cancer. 2013;13(13):385. https:\/\/doi.org\/10.1186\/1471-2407-13-385.","journal-title":"BMC Cancer"},{"issue":"10028","key":"3221_CR11","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/s0140-6736(15)01283-0","volume":"387","author":"P Sch\u00f6ffski","year":"2016","unstructured":"Sch\u00f6ffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. The Lancet. 2016;387(10028):1629\u201337. https:\/\/doi.org\/10.1016\/s0140-6736(15)01283-0.","journal-title":"The Lancet"},{"issue":"8","key":"3221_CR12","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1200\/JCO.2015.62.4734","volume":"34","author":"GD Demetri","year":"2016","unstructured":"Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol. 2016;34(8):786\u201393. https:\/\/doi.org\/10.1200\/JCO.2015.62.4734.","journal-title":"J Clin Oncol"},{"issue":"30s","key":"3221_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2217\/fon-2022-0517","volume":"18","author":"A Le Cesne","year":"2022","unstructured":"Le Cesne A, Mart\u00edn-Broto J, Grignani G. A review of the efficacy of trabectedin as second-line treatment of advanced soft tissue sarcoma. Future Oncol. 2022;18(30s):5\u201311. https:\/\/doi.org\/10.2217\/fon-2022-0517.","journal-title":"Future Oncol"},{"issue":"19","key":"3221_CR14","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1200\/JCO.2006.10.4117","volume":"25","author":"RG Maki","year":"2007","unstructured":"Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol. 2007;25(19):2755\u201363. https:\/\/doi.org\/10.1200\/JCO.2006.10.4117.","journal-title":"J Clin Oncol"},{"key":"3221_CR15","doi-asserted-by":"publisher","unstructured":"Garc\u00eda-Del-Muro X, L\u00f3pez-Pousa A, Maurel J, Mart\u00edn J, Mart\u00ednez-Trufero J, Casado A, et al (2011) Spanish Group for Research on Sarcomas. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol. 29(18): 2528\u201333. https:\/\/doi.org\/10.1200\/JCO.2010.33.6107","DOI":"10.1200\/JCO.2010.33.6107"},{"key":"3221_CR16","doi-asserted-by":"publisher","unstructured":"Van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al; EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 379(9829): 1879\u201386, https:\/\/doi.org\/10.1016\/S0140-6736(12)60651-5","DOI":"10.1016\/S0140-6736(12)60651-5"},{"key":"3221_CR17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.critrevonc.2015.10.020","volume":"98","author":"A Ducoulombier","year":"2016","unstructured":"Ducoulombier A, Cousin S, Kotecki N, Penel N. Gemcitabine-based chemotherapy in sarcomas: a systematic review of published trials. Crit Rev Oncol Hematol. 2016;98:73\u201380. https:\/\/doi.org\/10.1016\/j.critrevonc.2015.10.020.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"3221_CR18","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1200\/JCO.2002.11.050","volume":"20","author":"ML Hensley","year":"2002","unstructured":"Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002;20(12):2824\u201331. https:\/\/doi.org\/10.1200\/JCO.2002.11.050.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3221_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11864-018-0525-1","volume":"19","author":"IME Desar","year":"2018","unstructured":"Desar IME, Fleuren EDG, van der Graaf WTA. Systemic treatment for adults with synovial sarcoma. Curr Treat Options Oncol. 2018;19(2):13. https:\/\/doi.org\/10.1007\/s11864-018-0525-1.","journal-title":"Curr Treat Options Oncol"},{"issue":"2","key":"3221_CR20","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1200\/JCO.2017.75.1941","volume":"36","author":"leioS, Van Tine BA","year":"2018","unstructured":"leioS, Van Tine BA. Synovial sarcoma: current concepts and future perspectives. J Clin Oncol. 2018;36(2):180\u20137. https:\/\/doi.org\/10.1200\/JCO.2017.75.1941.","journal-title":"J Clin Oncol."},{"key":"3221_CR21","doi-asserted-by":"publisher","first-page":"102455","DOI":"10.1016\/j.ctrv.2022.102455","volume":"110","author":"S Stacchiotti","year":"2022","unstructured":"Stacchiotti S, Maria Frezza A, Demetri GD, Blay JY, Bajpai J, Baldi GG, et al. Retrospective observational studies in ultra-rare sarcomas A consensus paper from the connective tissue oncology society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments. Cancer Treat Rev. 2022;110:102455. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102455.","journal-title":"Cancer Treat Rev."},{"key":"3221_CR22","doi-asserted-by":"publisher","unstructured":"Van Glabbeke M, Verweij J, Judson I, Nielsen OS, EORTC Soft Tissue and Bone Sarcoma Group (2002) Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer. 38(4): 543\u20139. https:\/\/doi.org\/10.1016\/s0959-8049(01)00398-7","DOI":"10.1016\/s0959-8049(01)00398-7"},{"issue":"6","key":"3221_CR23","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1158\/1078-0432.CCR-08-2035","volume":"15","author":"AA Adjei","year":"2009","unstructured":"Adjei AA, Christian M, Ivy P. Novel designs and end points for phase II clinical trials. Clin Cancer Res. 2009;15(6):1866\u201372. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-2035.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"3221_CR24","first-page":"1079","volume":"4","author":"DD Von Hoff","year":"1998","unstructured":"Von Hoff DD. There are no bad anticancer agents, only bad clinical trial designs\u2013twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Clin Cancer Res. 1998;4(5):1079\u201386.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3221_CR25","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1093\/annonc\/mds470","volume":"24","author":"N Penel","year":"2013","unstructured":"Penel N, Demetri GD, Blay JY, Cousin S, Maki RG, Chawla SP, et al. Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy. Ann Oncol. 2013;24(2):537\u201342. https:\/\/doi.org\/10.1093\/annonc\/mds470.","journal-title":"Ann Oncol"},{"issue":"10","key":"3221_CR26","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1093\/annonc\/mdt278","volume":"24","author":"S Cousin","year":"2013","unstructured":"Cousin S, Blay JY, Bertucci F, Isambert N, Italiano A, Bompas E, et al. Correlation between overall survival and growth modulation index in pre-treated sarcoma patients: a study from the French sarcoma group. Ann Oncol. 2013;24(10):2681\u20135. https:\/\/doi.org\/10.1093\/annonc\/mdt278.","journal-title":"Ann Oncol"},{"issue":"1","key":"3221_CR27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.cct.2010.09.010","volume":"32","author":"S Kovalchik","year":"2011","unstructured":"Kovalchik S, Mietlowski W. Statistical methods for a phase II oncology trial with a growth modulation index (GMI) endpoint. Contemp Clin Trials. 2011;32(1):99\u2013107. https:\/\/doi.org\/10.1016\/j.cct.2010.09.010.","journal-title":"Contemp Clin Trials"},{"issue":"4","key":"3221_CR28","doi-asserted-by":"publisher","first-page":"792","DOI":"10.3390\/cancers13040792","volume":"13","author":"J Mart\u00ednez-Trufero","year":"2021","unstructured":"Mart\u00ednez-Trufero J, De Sande-Gonz\u00e1lez LM, Luna P, Martin-Broto J, \u00c1lvarez R, Marquina G, et al. A growth modulation index-based GEISTRA score as a new prognostic tool for trabectedin efficacy in patients with advanced soft tissue sarcomas: a Spanish group for sarcoma research (GEIS) retrospective study. Cancers (Basel). 2021;13(4):792. https:\/\/doi.org\/10.3390\/cancers13040792.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"3221_CR29","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1097\/CAD.0000000000000560","volume":"28","author":"A Buonadonna","year":"2017","unstructured":"Buonadonna A, Benson C, Casanova J, Kasper B, L\u00f3pez Pousa A, Mazzeo F, et al. A noninterventional, multicenter, prospective phase IV study of trabectedin in patients with advanced soft tissue sarcoma. Anticancer Drugs. 2017;28(10):1157\u201365. https:\/\/doi.org\/10.1097\/CAD.0000000000000560.","journal-title":"Anticancer Drugs"},{"issue":"6","key":"3221_CR30","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1002\/cncr.32661","volume":"126","author":"H Kobayashi","year":"2020","unstructured":"Kobayashi H, Iwata S, Wakamatsu T, Hayakawa K, Yonemoto T, Wasa J, et al. Efficacy and safety of trabectedin for patients with unresectable and relapsed soft-tissue sarcoma in Japan: a Japanese musculoskeletal oncology group study. Cancer. 2020;126(6):1253\u201363. https:\/\/doi.org\/10.1002\/cncr.32661.","journal-title":"Cancer"},{"key":"3221_CR31","doi-asserted-by":"publisher","unstructured":"Pautier P, Italiano A, Piperno-Neumann S, Chevreau C, Penel N, et al, French Sarcoma Group (2022) Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol. 23(8): 1044\u20131054. https:\/\/doi.org\/10.1016\/S1470-2045(22)00380-1","DOI":"10.1016\/S1470-2045(22)00380-1"},{"issue":"32","key":"3221_CR32","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.2217\/fon-2022-0348","volume":"18","author":"C Carroll","year":"2022","unstructured":"Carroll C, Patel N, Gunsoy NB, Stirnadel-Farrant HA, Pokras S. Meta-analysis of pazopanib and trabectedin effectiveness in previously treated metastatic synovial sarcoma (second-line setting and beyond). Future Oncol. 2022;18(32):3651\u201365. https:\/\/doi.org\/10.2217\/fon-2022-0348.","journal-title":"Future Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-023-03221-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-023-03221-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-023-03221-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T07:12:38Z","timestamp":1698304358000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-023-03221-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,17]]},"references-count":32,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3221"],"URL":"https:\/\/doi.org\/10.1007\/s12094-023-03221-6","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,17]]},"assertion":[{"value":"28 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AR reports honoraria and advisory\/consultancy (MSD, AstraZeneca, GSK, and PharmaMar); research grant\/funding to his institution (Eisai, PharmaMar, and Roche); travel\/accommodation\/expenses (AstraZeneca, PharmaMar, and Roche); and speakers bureau (MSD, AstraZeneca, GSK, Clovis, and PharmaMar), outside the submitted work. MM reports having received honoraria (MSD, AstraZeneca and GSK), research grant\/funding to her institution (Eisai and PharmaMar), and travel\/accommodation\/expenses (AstraZeneca, GSK, PharmaMar, Roche and Pfizer) outside the submitted work. The rest of the authors have declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individuals participants included in the study","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}